메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Seong Ho Hwang (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Hyang Suk Choi (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Yun Gyoung Kim (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Ji-Hyun Kim (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Min-Ki Seong (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Won Il Jang (Departments of Radiation Oncology Korea Cancer Center Hospital Korea Institute of Radiological and) Sang Min Youn (Departments of Neurosurgery Korea Cancer Center Hospital Korea Institute of Radiological and Medica) Hyun-Ah Kim (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci) Woo Chul Noh (Departments of Surgery Korea Cancer Center Hospital Korea Institute of Radiological and Medical Sci)
저널정보
한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제4권 제2호
발행연도
2016.12
수록면
85 - 91 (7page)
DOI
https://doi.org/10.14449/jbd.2016.4.2.85

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: The molecular subtype of breast cancer is an important predictive factor. Therefore, we investigated the effects of concurrent or serial radiotherapy and systemic therapy on metastatic brain lesions according to the molecular subtype of breast cancer. Methods: The present retrospective study examined data from 66 patients with breast cancer and metastatic brain lesions, who were treated using radiotherapy between January 1990 and July 2014. Patients were classified into the following three subtypes based on their hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status: HR+/HER2? (luminal A, 13 patients), HR+/HER2+ (luminal B, 21 patients), HR?/HER2+ (HER2, 22 patients), or HR?/HER2? (triple negative, 10 patients). The brain lesions and their responses to treatment were evaluated using brain computed tomography or magnetic resonance imaging. Progression of brain disease was defined by a ≥20% increase in the sum of the lesion’s diameters or the development of a new brain lesion. Progression-free survival was calculated from the initiation of radiotherapy to the first instance of brain disease progression or last follow-up. Results: Patients in the HER2 group who had received concurrent radiotherapy and systemic therapy (mainly HER2-targeted therapy) exhibited significantly better progression-free survival than did patients who had received radiotherapy followed by systemic therapy (p=0.037). However, concurrent radiotherapy and systemic therapy did not significantly improve progression-free survival in the luminal A (p=0.527), luminal B (p=0.462), or triple negative (p=0.558) groups. Conclusion: Concurrent radiotherapy and mainly HER2-targeted systemic therapy significantly prolonged progression-free survival in the HER2 group.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0